Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Male Breast Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Irvine
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
(+)-VINCRISTINE
University of Washington
Phase 2BBB

View all 50 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →